Recombinant Mouse CD300f/LMIR3 Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 10967-LM

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
10967-LM-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

NS0

Accession #

Q6SJQ7.1

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

View all CD300f/LMIR3 Proteins and Enzymes »

Product Specifications

Source

Mouse myeloma cell line, NS0-derived mouse CD300f/LMIR3 protein
CD300f/LMIR-3
(Cys16-Gly188)
Accession # Q6SJQ7.1		 IEGRMDP Mouse IgG2a
(Glu98-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Cys16 & Glu20

Predicted Molecular Mass

46 kDa

SDS-PAGE

55-65 kDa, under reducing conditions.

Activity

Measured by its ability to inhibit anti-CD3 antibody induced IL-2 or IFN-gamma secretion by human T cells. The ED50 for this effect 1.50-15.0 μg/mL.

Scientific Data Images for Recombinant Mouse CD300f/LMIR3 Fc Chimera Protein, CF

Recombinant Mouse CD300f/LMIR3 Fc Chimera Protein Bioactivity.

Measured by its ability to inhibit anti-CD3 antibody induced IL-2 secretion by human T cells. The ED50 for this effect 1.50 - 15.0 μg/mL.

Recombinant Mouse CD300f/LMIR3 Fc Chimera Protein SDS-PAGE.

2 μg/lane of Recombinant Mouse CD300f/LMIR3 Fc Chimera Protein (Catalog # 10967-LM) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 55-65 kDa and 110-130 kDa, respectively.

Formulation, Preparation and Storage

10967-LM
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CD300f/LMIR3

Leukocyte mono-immunoglobulin-like receptor 3 (LMIR3), also called CD300f and CLM-1, is a member of the paired immune receptor family within the immunoglobulin superfamily (1). Mature mouse LMIR3 consists of an extracellular domain (ECD) with one Ig-like V-type domain, a transmembrane segment, and a cytoplasmic domain that contains two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and immunoreceptor tyrosine-based switch motif (ITSM) (2). Alternate splicing generates additional isoforms with varying length C-terminal tails following the ECD (3). Within the ECD, mouse LMIR3 shares 43% amino acid (aa) sequence identity with human LMIR3. LMIR3 is expressed on the surface of dendritic cells, monocytes, granulocytes, and mast cells as well as on acute myeloid leukemia (AML) blasts (3, 4). Pervanadate treatment or antibody cross‑linking of LMIR3 induces phosphorylation of tyrosine residues in the cytoplasmic domain and the subsequent recruitment of phosphatases SHIP, SHP-1, SHP-2, and the p85 alpha subunit of PI3K (3, 5, 6). LMIR3 appears to exhibit a dual function in mast cells. LMIR3 functions as a negative regulator of MC activation through an inhibitory effect on Fc epsilonRI-mediated cytokine production in mast cells (5). Conversely, it enhances TLR4‑mediated signaling/cytokine production in mast cells through association with the activating signaling protein FcR gamma (5). Additionally, LMIR3 ligation can induce cell death and inhibit signaling through multiple receptors including Fc epsilon RI, LMIR4, SCF R, TLR2, TLR3, and TLR9 (3-8). In mouse, a splice variant of LMIR3 (known as DIgR2, with a 7 aa insertion in the ECD) inhibits CD4+ T cell activation and in vivo Th1 and CTL responses (9). LMIR3 is up‑regulated on monocytes surrounding experimentally-induced spinal cord demyelination and functions as a negative regulator of inflammation in the CNS (10).

References

  1. Clark, G.J. et al. (2009) Trends Immunol. 30:209.
  2. Izawa, K. et al. (2012) Immunity 37:827.
  3. Alvarez-Errico, D. et al. (2004) Eur. J. Immunol. 34:3690.
  4. Korver, W. et al. (2009) Leukemia 23:1587.
  5. Izawa, K. et al. (2009) J. Immunol. 183:925.
  6. Alvarez-Errico, D. et al. (2007) J. Immunol. 178:808.
  7. Can, I. et al. (2008) J. Immunol. 180:207.
  8. Izawa, K. et al. (2007) J. Biol. Chem. 282:17997.
  9. Shi, L. et al. (2006) Blood 108:2678.
  10. Xi, H. et al. (2010) J. Exp. Med. 207:7.

Long Name

Leukocyte Mono Ig-like Receptor 3

Alternate Names

CD300f, CD300LF, CLIM1, CLM1, DIgR2, IGSF13, IREM-1, LMIR3, NKIR, Pigr3

Entrez Gene IDs

146722 (Human); 246746 (Mouse)

Gene Symbol

CD300LF

UniProt

Q6SJQ7.1

Additional CD300f/LMIR3 Products

Product Documents for Recombinant Mouse CD300f/LMIR3 Fc Chimera Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Mouse CD300f/LMIR3 Fc Chimera Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.